diaDexus recent weakness brings attractive entry point, says Ladenburg Ladenburg says the recent weakness in shares of diaDexus presents an attractive entry point into the name. The firm expects fundamentals of the company's Lp-PLA2 franchise to strengthen over the next 6-12 months and it reiterates a Buy rating on the stock with a $1.75 price target.
diaDexus says Chief Business Officer Richey to leave company diaDexus announced that Michael Richey, chief business officer, will be leaving the company effective September 30. The company has initiated a search for a chief commercial officer. Paul Manners will oversee the company's commercial operations in an interim role until the CCO role is filled. Manners was previously vice president, Global Finance and Marketing at Novartis Diagnostics and also held executive finance and commercial positions within Johnson & Johnsonís pharmaceutical and medical device businesses.